Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Post by edroseon Mar 15, 2023 5:56pm
403 Views
Post# 35341209

What ever happened to 4050 Lynne gagnon pierre laurin and do

What ever happened to 4050 Lynne gagnon pierre laurin and doDoc moran plus other scientists showing us great results in humans during each agm and during quarterly updates  then suddenly after takeover all previous research was cancelled and they sold plasma division with excellent results was sold for ridiculous low price few weeks before ryplasim was approved by fda and ivig also no problems and great results 
I wonder what the company who bought plasma division is doing with plasma patented division they bought 
luminal appears years away from potentially getting a product approved
maybe analysts can ask questions about timelines re research 
nobody really replaced doc Lynne gagnon and her team since she left after takeover 
<< Previous
Bullboard Posts
Next >>